FINWIRES · TerminalLIVE
FINWIRES

Elastic Q1 Adjusted Earnings, Revenue Rise; Shares Surge After Hours

By

Elastic (ESTC) reported fiscal Q1 non-GAAP earnings late Thursday of $0.70 per diluted share, up from $0.60 a year earlier.

Analysts polled by FactSet expected $0.58.

Revenue in the three months ended July 31 rose to $478.1 million from $415.3 million a year earlier.

Analysts projected $469.7 million.

The company expects fiscal Q2 non-GAAP EPS of $0.80 to $0.82 on revenue of $486 million to $487 million.

Analysts project EPS of $0.79 on revenue of $483.5 million.

Elastic boosted fiscal 2027 guidance to non-GAAP EPS of $3.29 to $3.37 on revenue of $1.998 billion to $2.01 billion, up from the prior forecast of EPS of $3.21 to $3.29 on revenue of $1.985 billion to $2 billion.

Analysts expect EPS of $3.24 on revenue of $1.996 billion.

Elastic shares jumped 22% in after-hours trading.

Related Articles

Wire

Update: Magellan Financial Group Fiscal 2026 Operating Earnings, Revenue Down; Shares Fall 12%

(Updates to add stock movement in the headline and the last paragraph)Magellan Financial Group (ASX:MFG) logged AU$0.828 in operating earnings per share for fiscal 2026, compared with AU$0.898 a year ago, a Thursday filing showed.For the 12 months ended June 30, revenue and other income was AU$195.6 million versus AU$318.9 million previously, the Australia-listed financial services firm added.The board declared a final dividend of AU$0.255 per share, payable Sept. 16 to shareholders on record as of Sept. 2. A year ago, the company paid a final dividend AU$0.259 per share and special dividend of AU$0.21 per share.The board has revised the group's dividend policy from fiscal 2027, targeting a payout ratio of 60% to 90% of operating profit after tax.The company's shares fell 12% in recent Thursday trade.

ASX:MFG
Wire

Tenable to Join S&P SmallCap 600 Index

Tenable (TENB) will join the S&P SmallCap 600 index before market open on Aug. 31, the S&P Dow Jones Indices said in a late Wednesday statement.Tenable will replace Leggett & Platt (LEG), which is being acquired by Somnigroup International (SGI), according to the statement.

$LEG$SGI$TENB
Wire

NeoGenomics Wins Expanded Medicare Coverage for RaDaR ST Immunotherapy Monitoring

NeoGenomics (NEO) said its RaDaR ST molecular residual disease assay received expanded Medicare coverage to include immunotherapy response monitoring for patients with late-stage solid tumors.The determination from the Centers for Medicare & Medicaid Services' Molecular Diagnostic Services Program is the third Medicare-covered indication for RaDaR ST, NeoGenomics said Wednesday in a statement.The coverage allows use of the assay to monitor response to immune-checkpoint inhibitor therapy, and NeoGenomics said it has two additional RaDaR ST submissions pending.NeoGenomics shares rose 2.1% in after-hours trading.

$NEO